Conaghan, Philip GPhilip GConaghanPavelka, KarelKarelPavelkaSONG-CHOU HSIEHBonnington, Terri-LeighTerri-LeighBonningtonKent, Toby CToby CKentMarchbank, KatieKatieMarchbankEdwards, Christopher JChristopher JEdwards2023-09-192023-09-1920232514-1775https://www.scopus.com/record/display.uri?eid=2-s2.0-85160670207&doi=10.1093%2frap%2frkad017&origin=inward&txGid=829a525d6a0bdf668f43e6d51a33943fhttps://scholars.lib.ntu.edu.tw/handle/123456789/635432Moderately active RA is associated with poor patient outcomes. Despite this, some health systems have restricted access to advanced therapies to those with severe RA. There is also limited evidence of the efficacy of advanced therapies in the moderately active RA population. This post-hoc analysis from four phase 3 trials explored the efficacy of upadacitinib (UPA) for moderately active RA.enJAK inhibitors; RA; moderate; moderate disease activity; upadacitinibjournal article10.1093/rap/rkad017367942832-s2.0-85160670207https://api.elsevier.com/content/abstract/scopus_id/85160670207